One of the most common challenges for drug developers pursuing global IND submissions is insufficient planning. Initiating your global IND submission too late can leave you vulnerable to rushed timelines, gaps in expertise and miscalculated regulatory requirements, all of which can affect the acceptability of an application. Working with the right laboratory testing partner can help you navigate these challenges and make your IND as strong as it can be.
Working with WuXi AppTec, you will have:
- Bioanalytical services that support drug discovery and seamlessly move programs from preclinical to clinical development.
-
DMPK services with comprehensive in vitro and in vivo ADME solutions from high-throughput screening in discovery throught development phases.
-
Safety assessment services features a skilled team of toxicologists who provide comprehensive safety assessments across a wide range of species and through various routes of administration.
-
The Central Laboratory provides services that closely connect sponsors, industries, clinical sites and testing labs that support Phase I-IV clinical studies in the global pharmaceutical industry.
-
A variety of animal species to meet your needs.
-
Current NHP availability for your studies.
-
Immediate and flexible start times.
-
Available capacity.